Search This Blog

Monday, October 19, 2026

AnaptysBio says partner GSK wins FDA nod for Jemperli in MSI-H/dMMR locally advanced rectal cancer

 

expanding indications and AnaptysBio royalty potential

  • Jemperli becomes the first and only immunotherapy option for adults with MSI-H/dMMR locally advanced rectal cancer.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)